Monique (26 yrs) shares her story of getting back on track after going off diet for a number of years
Con (51 yrs) shares his regrets about being off diet for 37 years
Bianca (29 yrs) shares her experience of managing PKU with a strict diet
Katy (41 yrs) shares her challenges of managing PKU during pregnancy
Josh & Tom (13 & 11 yrs) and Mum, talk about family life with PKU and their initial experiences with KUVAN®
Please contact us for more information.
BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
NAGLAZYME® is indicated as long term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, Nacetylgalactosamine 4- sulfatase deficiency, Maroteaux-Lamy syndrome).
VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis type IVA, morquio A syndrome).
VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.